Ghent University Academic Bibliography

Show Sort by

Your filters: cql: author="Anguille, Sébastien" or (type any "bookEditor issueEditor" and editor="Anguille, Sébastien")

Add to list
- Journal Article
- A1
- open access
Chimeric antigen receptor-T-cell therapy for B-cell hematological malignancies : an update of the pivotal clinical trial data

Gils Roex, Tom Feys, Yves Beguin, Tessa Kerre (UGent) , Xavier Poire, Philippe Lewalle, Peter Vandenberghe, Dominique Bron and Sebastien Anguille

(2020) PHARMACEUTICS. 12(2).
Add to list
- Conference Paper
- C3
Phase 1 studies assessing the safety and clinical activity of multiple doses of a NKG2D-based CAR-T therapy, Cyad-01, in acute myeloid leukemia

Jason B Brayer, David A Sallman, Tessa Kerre (UGent) , Xavier Poire, Violaine Havelange, Philippe Lewalle, Eunice S Wang, Dominik Selleslag, Sebastien Anguille, Yves Beguin, et al.

(2018) BLOOD. 132(suppl. 1).
Add to list
- Journal Article
- A1
- open access
The tumor-associated antigen RHAMM (HMMR/CD168) is expressed by monocyte-derived dendritic cells and presented to T cells

Yannick Willemen, Johan M. J. Van den Bergh, Sarah Bonte (UGent) , Sebastien Anguille, Carlo Heirman, Barbara MH Stein, Herman Goossens, Tessa Kerre (UGent) , Kris Thielemans, Marc Peeters, et al.

(2016) ONCOTARGET. 7(45). p.73960-73970
Add to list
- Journal Article
- A1
- open access
Design of an optimized Wilms' tumor 1 (WT1) mRNA construct for enhanced WT1 expression and improved immunogenicity in vitro and in vivo

Daphné Benteyn, Sébastien Anguille, Sandra Van Lint (UGent) , Carlo Heirman, An MT Van Nuffel, Jurgen Corthals, Sebastian Ochsenreither, Wim Waelput, Katrien Van Beneden, Karine Breckpot, et al.

(2013) MOLECULAR THERAPY-NUCLEIC ACIDS. 2.

Academic Bibliography

Chimeric antigen receptor-T-cell therapy for B-cell hematological malignancies : an update of the pivotal clinical trial data

Phase 1 studies assessing the safety and clinical activity of multiple doses of a NKG2D-based CAR-T therapy, Cyad-01, in acute myeloid leukemia

The tumor-associated antigen RHAMM (HMMR/CD168) is expressed by monocyte-derived dendritic cells and presented to T cells

Design of an optimized Wilms' tumor 1 (WT1) mRNA construct for enhanced WT1 expression and improved immunogenicity in vitro and in vivo

Contents

Support

Contact